Gender-Specific Effects on Verapamil Pharmacokinetics and Pharmacodynamics in Humans

Journal of Clinical Pharmacology

Volumn 40, Issue 3, 2000, Pages 219-230

  Krecic Shepard, Mary Ellen ^a   Barnas, Crissy R ^a   Slimko, Jill ^a   Jones, Michael P ^a   Schwartz, Janice B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYP3A PROTEIN, HUMAN; CYTOCHROME P450; DIAGNOSTIC AGENT; ERYTHROMYCIN; MIXED FUNCTION OXIDASE; VERAPAMIL;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; BLOOD PRESSURE; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYMOLOGY; FEMALE; HEART RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; BREATH TESTS; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; FEMALE; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; SEX FACTORS; VERAPAMIL;

EID: 0034145948     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008883     Document Type: Article

References (63)

1. Busse D, Cosme J, Beaune P, Kroemer H, Eichelbaum M: Cytochromes of the P4502C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn-Schmiedeberg's Arch Pharmacol 1995;353:116-121.
2. Kroemer H, Gautier J, Beaune P, Henderson C, Wolf C, Eichelbaum M: Identification of P450 enzymes involved in metabolism of verapamil in humans. Arch Pharmacol 1993;348:332-337.
3. Stein W: Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiological Reviews 1997;77(2):545-590.
4. Sandstrom R, Karlsson S, Knutson L, Lennernas H: Jejunal absorption and metabolism of R/S verapamil in humans. Pharm Res 1998; 15(6):856-862.
5. Schwartz J: Aging alters verapamil elimination and dynamics: single dose and steady-state responses. J Pharmacol Exp Ther 1990;255: 364-373.
6. Schwartz J, Troconiz I, Verotta D, Liu S, Capili H: Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. J Pharmacol Exp Ther 1993;265:690-698.
7. Schwartz J, Capili H, Daugherty J: Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994;55:509-517.
8. Schwartz J, Capili H, Wainer I: Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. Clin Pharmacol Ther 1994;55:509-517.
9. Krecic-Shepard M, Barnas C, Slimko J, Gorski J, Wainer I, Schwartz J: In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 1999;66:40-50.
10. Abernethy D, Schwartz J, Todd E, Luchi R, Snow E: Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Ann Intern Med 1986;105:329-336.
11. Abernethy D, Wainer I, Longstreth J, Andrawis N: Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. J Pharmacol Exp Ther 1993;266:904-911.
12. Gupta S, Atkinson L, Tu T, Longstreth J: Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. Br J Clin Pharmacol 1995;40(4): 325-331.
13. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS: Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989;83:688-697.
14. Yong C, Kunka R, Bates T: Factors affecting the plasma protein binding of verapamil and norverapamil in man. Res Commun Chem Pathol Pharmacol 1980;30:329-339.
15. Harris R, Benet L, Schwartz J: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50(2):222-239.
16. Fletcher C, Acosta E, Strykowski J: Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 1994; 15(8):619-629.
17. Hooper WD, Qing M-S: The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clin Pharmacol Ther 1990;48:633-640.
18. Ho P, Triggs E, Bourne D, Heazlewood V: The effects of age and sex on the disposition of acetylsalicyclic acid and its metabolites. Br J Clin Pharmacol 1985;19:675-684.
19. Kristjansson F: Disposition of alprazolam in human volunteers: differences between genders. Acta Pharm Nord 1991;3:249-250.
20. Pritchard J, Bryson J, Kernodle A, Benedetti T, Powell J: Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther 1992;51:51-55.
21. Nafziger A, Bertino J: Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol 1989;37:97-100.
22. Hunt C, Westerkam W, Stave G: Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-283.
23. Milano G, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, et al: Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992;10:1171-1175.
24. Prather R, Tu T, Rolf C, Gorsline J: Nicotine pharmacokinetics of Nicoderm® (nicotine transdermal system) in women and obese men compared with normal-sized men. J Clin Pharmacol 1993;33:644-649.
25. Lew K, Ludwig E, Milad M, Donovan K, Middleton E, Ferry J, et al: Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993;54:402-414.
26. Hulst L, Fleishaker J, Peters G, Harry J, Wright D, Ward P: Pharmacokinetics and drug disposition: effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 1994;55(4):378-384.
27. Meffin P, Brooks P, Sallustio B: Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol 1984;17:395-404.
28. Wilson K: Sex-related differences in drug disposition in man. Clin Pharmacokinet 1984;9:189-202.
29. Sasaki M, Tateishi T, Ebihara A: The effects of age and gender on the stereoselective pharmacokinetics of verapamil. Clin Pharmacol Ther 1993;54:278-285.
30. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
31. Greenblatt D, Abernethy D, Locniskar A, Harmatz J, Limjuco R, Shader R: Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984;61(1):27-35.
32. Gorski J, Jones D, Haehner-Daniels B, Hamman M, O'Mara E, Hall S: The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64(2):133-143.
33. Nishiyama T, Matsukawa T, Hanaoka K: The effects of age and gender on the optimal premedication dose of intramuscular midazolam. Anesth Analges 1998;86:1103-1108.
34. Austin K, Mather L, Philpot C, McDonald P: Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10:273-279.
35. Hunt C, Westerkam W, Stave G, Wilson J: Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. Mech Ageing Dev 1992;64: 189-199.
36. Lukkari E, Hakonen T, Neuvonen P: The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids. Eur J Clin Pharmacol 1998;53(5):351-354.
37. Marathe P, Greene D, Lee J, Barbhaiya R: Assessment of effect of food, gender, and intra-subject variability in the pharmacokinetics of avitriptan. Biopharm Drug Disp 1998;19(3):153-157.
38. Barbhaiya R, Knupp C, Pittman K: Effects of age and gender on pharmacokinetics of cefepime. Antimicrob Agents Chemother 1992; 36:1181-1185.
39. Keung A, Eller M, Weir S: Single-dose pharmacokinetics of rifapentine in women. J Pharmacokin Biopharm 1998;26(1):75-85.
40. Minto C, Schnider T, Egan T, Youngs E, Lemmens H, Gambus P, et al: Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil: I. Model development. Anesthesiology 1997;86(1):10-23.
41. Gorski J, Lin Z, Bruce M, Craven R, Haehner-Daniels B, Hall S: The interaction between CYP3A substrates in the elderly. Clin Pharmacol Ther 1999;65(2):136.
42. Thummel K, Shen D, Podoll T, Kunze K, Trager W, Bacchi C, et al: Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intra-individual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271(1):557-566.
43. Rosenberg D: Dietary modulation of cytochrome P450 in the small intestinal epithelium. Pharmacology 1991;43:36-46.
44. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, et al: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-2553.
45. Darbar D, Dell'Orto S, Morike K, Wilkinson G, Roden D: Dietary salt increases first-pass elimination of oral quinidine. Clin Pharmacol Ther 1997;61:292-300.
46. Van Horn L, Ballew C, Liu K, Ruth K, McDonald A, Hilner J, et al: Diet, body size, and plasma lipids-lipoproteins in young adults: differences by race and sex. The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 1991; 133:9-23.
47. Pantuck E, Pantuck C, Garland W, Min B, Wattenberg L, Anderson K, et al: Stimulatory effects of brussel sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979;25:88-95.
48. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, et al: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLS-PK1). J Pharmacol Exp Ther 1992;263:840-845.
49. Cavet M, West M, Simmons N: Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 1996;118:1389-1396.
50. Kates R, Keefe D, Schwartz J, Harapat S, Kirsten E, Harrison D: Verapamil disposition kinetics in chronic atrial fibrillation. Clin Pharmacol Ther 1981;30:44-51.
51. Ricci M, Toscano D, Mattingly C, Toscano W Jr: Estrogen receptor reduces CYP1A1 induction in cultured human endometrial cells. J Bio Chem 1999;274(6):3430-3438.
52. Fazio A: Oral contraceptive drug interactions: important considerations. South Med J 1991;84:997-1002.
53. Back D, Orme M: Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18:472-484.
54. Crawford P, Chadwick D, Martin C, Tjia J, Back D, Orme M: The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990;30:892-896.
55. Shapiro B, Agrawal A, Pampori N: Gender differences in drug metabolism regulated by growth hormone. Internat J Biochem & Cell Biol 1995;27(1):9-20.
56. Teichmann A: Influence of oral contraceptives on drug therapy. Am J Obstet Gynecol 1990;163:2208-2213.
57. Jochemsen R, Van Der Graaff M, Boeijinga J, Breimer D: Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. Br J Clin Pharmacol 1982;13:319-324.
58. Holazo A, Winkler M, Patel I: Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol 1988;28(11):1040-1045.
59. Kashuba A, Nafziger A: Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet 1998;34(3):203-218.
60. Kharasch E, Russell M, Carton K, Lentz G, Bowdle T, Cox K: Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology 1997;87: 26-35.
61. Llerena A: Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Phamacokinet 1996; 21(2):129-138.
62. Schwartz J, Abernethy D, Taylor A, Mitchell J: An investigation of the cause of accumulation of verapamil during regular dosing in patients. Br J Clin Pharmacol 1985;19:512-516.
63. Harder S, Thurmann P, Siewert M, Blume H, Huber T, Rietbrock N: Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation. J Cardiovasc Pharmacol 1991;17:207-212.